US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,431.19

-12.3264-0.85%

Number of Gainers:8

Number of Losers:11

Number of Flat:- -

PE:- -

High:1,444.76

Open:1,443.61

Low:1,430.85

Close:1,443.52

Loading ...

This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?

Trump Backs FBI Intervention As Texas Republicans Hunt Democrats Amid Quorum Crisis

Benzinga_recent_news

Moderna (MRNA) Gets a Hold from Bernstein

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Benzinga_recent_news

Novavax Shares up 19% After Better-Than-Expected Quarterly Revenue

THOMSON REUTERS

BUZZ-Street View: Pfizer’s pipeline progress sparks long-term optimism despite margin risks

Novavax Exec Says Co Continues to Work With Barda on Potential Funding for Pandemic Influenza Vaccine Candidate - Conf Call

THOMSON REUTERS

BRIEF-Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program

Arvinas Inc. Unveils Presentation on Transformative Advances in Cancer and Neurodegenerative Disease Therapies

Vir Biotechnology Successfully Initiates All Trials in Eclipse Registrational Program for Chronic Hepatitis Delta

THOMSON REUTERS

Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Novavax Outlook 2025 Adj Revenue $1 Bln and $1.05 Bln VS Ibes Estimate $1.02 Bln

THOMSON REUTERS

Novavax: to Conduct Nuvaxovid Study on Behalf of Sanofi, Co Will Be Reimbursed About $55 Mln (at Midpoint) or 70% of Total Costs

THOMSON REUTERS

Novavax Outlook 2025 Combined R&D and SG&a Expenses $495 Mln - $545 Mln

THOMSON REUTERS

Novavax: Postmarketing Commitment Study on Nuvaxovid Anticipated to Occur During 2025 & 2026

THOMSON REUTERS

Novavax Inc - Reports Total Revenue of $239.2 Mln for Q2 2025 - SEC Filing

THOMSON REUTERS

Novavax Inc -Q2 EPS $0.62

THOMSON REUTERS

Commerzbank (0RLW) Gets a Hold from Warburg Research

US Health Department Ending Federal mRNA Vaccine Development

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1431.1898,"timestamp":1754510399999,"preClose":1443.5162,"halted":0,"volume":135632229,"delay":0,"changeRate":-0.008539,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-12.326416,"latestTime":"08-06 16:00:00 EDT","open":1443.6079,"high":1444.7598,"low":1430.8452,"amount":5428575658.557331,"amplitude":0.009639,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754573400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.784888,"peRate":20.505742,"turnoverRate":0.008858,"increases":8,"decrements":11,"flats":0,"marketCap":1180233409478.75,"floatMarketCap":1159266516220},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1444.7598,"amplitude":0.009639,"preClose":1443.5162,"low":1430.8452,"pbRate":"3.784888","latestPrice":1431.1898,"volume":135632229,"delay":0,"open":1443.6079,"prevYearClose":1274.8187,"prevWeekClose":1416.0137,"prevMonthClose":1401.1527,"prevQuarterClose":1377.5769,"fiveDayClose":1436.2535,"twentyDayClose":1401.8469,"sixtyDayClose":1327.5806,"secType":"PLATE","market":"US","turnoverRate":0.008858,"peRate":20.505742,"marketCap":1180233409478.75,"floatMarketCap":1159266516220,"timestamp":1754510399999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":8,"down":11,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557556012","title":"This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2557556012","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557556012?lang=en_us&edition=fundamental","pubTime":"2025-08-07 17:57","pubTimestamp":1754560620,"startTime":"0","endTime":"0","summary":"Meeting its dividend commitment this year should be a breeze, but the path ahead is much harder to predict.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828046%2Finvestor-individual-stock-charts-getty.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828046%2Finvestor-individual-stock-charts-getty.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/08/07/this-7-yielding-stock-just-raised-its-profit-forec/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BLSP4239.USD","LU1023059063.AUD","LU0225284248.USD","LU0170899867.USD","IE00B19Z3581.USD","BK4568","BK4585","SGXZ57979304.SGD","BK4581","LU0321505439.SGD","LU1057294990.SGD","LU0122379950.USD","BK4533","PFE","LU1066051498.USD","LU1066053197.SGD","LU0289739699.SGD","BK4592","IE00BBT3K403.USD","LU0868494617.USD","SG9999013999.USD","LU0306807586.USD","LU0225771236.USD","IE000M9KFDE8.USD","BK4007","BK4550","BK4588","SG9999001176.SGD","SG9999011175.SGD","LU0234572021.USD","SG9999002232.USD","BK4599","SG9999002224.SGD","LU1894683348.USD","IE0002270589.USD","IE00BLSP4452.SGD","SG9999001176.USD","LU1894683264.USD","LU0456855351.SGD","LU1883839398.USD","LU0306806265.USD","IE00B19Z3B42.SGD","LU0058720904.USD","SG9999003800.SGD","BK4534","LU0985481810.HKD","LU0321505868.SGD"],"gpt_icon":1},{"id":"2557860539","title":"Trump Backs FBI Intervention As Texas Republicans Hunt Democrats Amid Quorum Crisis","url":"https://stock-news.laohu8.com/highlight/detail?id=2557860539","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557860539?lang=en_us&edition=fundamental","pubTime":"2025-08-07 14:06","pubTimestamp":1754546760,"startTime":"0","endTime":"0","summary":"Texas Republicans seek FBI help to locate Democrats who fled state to block redistricting plan. GOP leaders push for arrests and legal action.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/07/Washington-D-c---Usa---April-7--2025-Uni.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/07/Washington-D-c---Usa---April-7--2025-Uni.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/politics/25/08/46949190/trump-backs-fbi-intervention-as-texas-republicans-hunt-democrats-amid-quorum-crisis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE00BJT1NW94.SGD","LU2089984988.USD","BK4588","LU1691799644.USD","IE00B4R5TH58.HKD","LU2237957902.USD","BK4592","LU2237957811.SGD","LU1914381329.SGD","BK4585","SG9999002232.USD","IE0009355771.USD","LU1989763427.SGD","IE00B2B36J28.USD","LU0266013472.USD","IE00BJJMRZ35.SGD","LU1721429741.USD","IE0002141913.USD","LU0122379950.USD","SG9999002224.SGD","BK4082","BK4566","LU1061106388.HKD","BK4581","LU1057294990.SGD","LU1721429402.USD","SGXZ23171101.USD","IE00BFTCPJ56.SGD","ABT","LU0170899867.USD","LU2133065610.SGD","LU2211815571.USD","BK4504","LU1989763690.USD","SG9999004303.SGD","LU0234572021.USD","LU1023059063.AUD","LU0868494617.USD","LU2468319806.SGD","LU2112291526.USD","BK4533","BK4568"],"gpt_icon":0},{"id":"2557506535","title":"Moderna (MRNA) Gets a Hold from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2557506535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557506535?lang=en_us&edition=fundamental","pubTime":"2025-08-07 13:15","pubTimestamp":1754543731,"startTime":"0","endTime":"0","summary":"Bernstein analyst Courtney Breen reiterated a Hold rating on Moderna on August 5 and set a price target of $28.00. The company’s shares closed yest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moderna-mrna-gets-a-hold-from-bernstein-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moderna-mrna-gets-a-hold-from-bernstein-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4588","BK4534","BK4533","BK4139","BK4532","BK4548","MRNA","BK4501","BK4585","BK4568"],"gpt_icon":0},{"id":"2557630770","title":"Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2557630770","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557630770?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:05","pubTimestamp":1754510700,"startTime":"0","endTime":"0","summary":"Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug.  06, 2025  (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT)today announced it will provide a business update and report financi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128660/25416/en/Vaxart-to-Host-Second-Quarter-2025-Business-Update-and-Financial-Results-Conference-Call-on-August-13.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXRT","BK4585","BK4568","BK4139","HST","BK4181","BK4218"],"gpt_icon":0},{"id":"2557306390","title":"RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2557306390","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557306390?lang=en_us&edition=fundamental","pubTime":"2025-08-06 23:49","pubTimestamp":1754495340,"startTime":"0","endTime":"0","summary":"Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/06/Washington--January-29-2025-Robert-F--Ke.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/06/Washington--January-29-2025-Robert-F--Ke.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/legal/25/08/46908847/eli-lilly-amgen-legal-fight-drug-discount-program","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LLY","LU2361044949.HKD","JNJ","LU2360106947.USD","LU0234572021.USD","LU2750360641.GBP","BK4592","LU0109391861.USD","IE00BJJMRZ35.SGD","LU0345770308.USD","IE0002270589.USD","LU0345770993.USD","LU0109394709.USD","LU2211815571.USD","LU1267930730.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2430703251.USD","LU2471134796.USD","LU2237443382.USD","LU2471134952.CNY","LU2602419157.SGD","LU0238689110.USD","LU1585245621.USD","LU1868837300.USD","IE00BVYPNV92.GBP","LU1868836914.USD","SG9999001440.SGD","GB00BDT5M118.USD","LU0320765992.SGD","LU2129689431.USD","HHS","IE00BK4W5L77.USD","AMGN","BK4532","LU1571399168.USD","LU0354030438.USD","LU1061106388.HKD","LU1804176565.USD","LU0823434740.USD","LU1232071149.USD","LU1221951129.SGD","BK4568","LU1720051017.SGD","LU1093756325.SGD","SGXZ51526630.SGD","LU0058720904.USD","LU1674673428.USD","BK4585","LU0795875169.SGD"],"gpt_icon":1},{"id":"2557847303","title":"Novavax Shares up 19% After Better-Than-Expected Quarterly Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2557847303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557847303?lang=en_us&edition=fundamental","pubTime":"2025-08-06 22:29","pubTimestamp":1754490573,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nL4N3TY1MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","BK4585","BK4547","NVAX","BK4588"],"gpt_icon":0},{"id":"2557704653","title":"BUZZ-Street View: Pfizer’s pipeline progress sparks long-term optimism despite margin risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2557704653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557704653?lang=en_us&edition=fundamental","pubTime":"2025-08-06 21:39","pubTimestamp":1754487576,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Pfizer’s pipeline progress sparks long-term optimism despite margin risks** Pfizer PFE.N said on Tuesday its full-year profit should benefit from cost cuts across research and manufa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nL4N3TJ0ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","BK4588","BK4534","BK4550","IE000M9KFDE8.USD","BK4592","LU0321505439.SGD","BK4585","LU0306807586.USD","SG9999002232.USD","BK4599","SG9999001176.USD","IE00B19Z3581.USD","LU1894683264.USD","LU0306806265.USD","LU0985481810.HKD","LU1066051498.USD","IE0002270589.USD","LU0225284248.USD","LU0456855351.SGD","LU0225771236.USD","LU0122379950.USD","SG9999002224.SGD","LU1883839398.USD","IE00BLSP4452.SGD","BK4581","LU1057294990.SGD","SG9999001176.SGD","LU0058720904.USD","SG9999013999.USD","SGXZ57979304.SGD","LU1894683348.USD","SG9999003800.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU0170899867.USD","LU0321505868.SGD","BK4007","IE00BBT3K403.USD","LU0234572021.USD","LU1066053197.SGD","LU0289739699.SGD","LU1023059063.AUD","LU0868494617.USD","PFE","BK4533","BK4568"],"gpt_icon":1},{"id":"2557772653","title":"Novavax Exec Says Co Continues to Work With Barda on Potential Funding for Pandemic Influenza Vaccine Candidate  - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2557772653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557772653?lang=en_us&edition=fundamental","pubTime":"2025-08-06 21:21","pubTimestamp":1754486477,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY25X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","NVAX","BK4547","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2557729913","title":"BRIEF-Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2557729913","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557729913?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:42","pubTimestamp":1754484144,"startTime":"0","endTime":"0","summary":"BRIEF-Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program Aug 6 (Reuters) - Vir Biotechnology Inc VIR.O:VIR BIOTECHNOLOGY SUCCESSFULLY INITIATES ALL TRIALS IN ECLIPSE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4585","BK4139","BK4568","BK4535"],"gpt_icon":0},{"id":"2557937424","title":"Arvinas Inc. Unveils Presentation on Transformative Advances in Cancer and Neurodegenerative Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2557937424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557937424?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:20","pubTimestamp":1754482835,"startTime":"0","endTime":"0","summary":"Arvinas Inc., a NASDAQ-listed company, has released a corporate presentation highlighting its advancements in developing therapeutics for cancer and neurodegenerative diseases. The presentation outlines Arvinas' unique therapeutic modality, PROTAC, and details the progress of six programs that have entered clinical trials over the past five years. These trials target significant unmet needs in areas such as oncology and neuroscience. Arvinas has also established multiple collaborations, including partnerships with Pfizer, Genentech, and Bayer, to develop novel PROTAC medicines and applications in various fields. The company has a global out-licensing agreement for luxdegalutamide, their androgen receptor degrader, and a co-development agreement for vepdegestrant, their estrogen receptor degrader. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL2H9TgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","LU1023059063.AUD","LU0225284248.USD","LU0170899867.USD","IE00B19Z3581.USD","BK4568","BK4585","SGXZ57979304.SGD","BK4581","LU0321505439.SGD","LU1057294990.SGD","LU0122379950.USD","BK4533","LU1066051498.USD","ARVN","LU1066053197.SGD","LU0289739699.SGD","BK4592","IE00BBT3K403.USD","LU0868494617.USD","SG9999013999.USD","LU0306807586.USD","LU0225771236.USD","IE000M9KFDE8.USD","BK4007","BK4550","BK4588","SG9999001176.SGD","SG9999011175.SGD","LU0234572021.USD","SG9999002232.USD","BK4599","SG9999002224.SGD","LU1894683348.USD","IE0002270589.USD","IE00BLSP4452.SGD","SG9999001176.USD","LU1894683264.USD","LU0456855351.SGD","LU1883839398.USD","LU0306806265.USD","IE00B19Z3B42.SGD","LU0058720904.USD","SG9999003800.SGD","BK4534","LU0985481810.HKD","LU0321505868.SGD"],"gpt_icon":1},{"id":"2557374365","title":"Vir Biotechnology Successfully Initiates All Trials in Eclipse Registrational Program for Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2557374365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557374365?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:12","pubTimestamp":1754482369,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","VIR","BK4585","BK4139","BK4568"],"gpt_icon":0},{"id":"2557743833","title":"Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2557743833","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557743833?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:05","pubTimestamp":1754481935,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta . The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL931KNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4585","BK4139","BK4568","BK4535"],"gpt_icon":0},{"id":"2557837144","title":"Novavax Outlook 2025 Adj Revenue $1 Bln and $1.05 Bln VS Ibes Estimate $1.02 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2557837144","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557837144?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:01","pubTimestamp":1754481686,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nP8N3FY03T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVAX","BK4568","BK4139","BK4588","BK4547","BK4585"],"gpt_icon":0},{"id":"2557737149","title":"Novavax: to Conduct Nuvaxovid Study on Behalf of Sanofi, Co Will Be Reimbursed About $55 Mln (at Midpoint) or 70% of Total Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2557737149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557737149?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:01","pubTimestamp":1754481686,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nP8N3FY03T:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BK4568","BK4585","NVAX","BK4588"],"gpt_icon":0},{"id":"2557465371","title":"Novavax Outlook 2025 Combined R&D and SG&a Expenses $495 Mln - $545 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2557465371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557465371?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:01","pubTimestamp":1754481686,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nP8N3FY03T:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","NVAX","BK4547","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2557450371","title":"Novavax: Postmarketing Commitment Study on Nuvaxovid Anticipated to Occur During 2025 & 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2557450371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557450371?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:01","pubTimestamp":1754481686,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nP8N3FY03T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BK4585","BK4568","BK4588","NVAX"],"gpt_icon":0},{"id":"2557893371","title":"Novavax Inc - Reports Total Revenue of $239.2 Mln for Q2 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2557893371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557893371?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:49","pubTimestamp":1754480953,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY11R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVAX","BK4568","BK4139","BK4588","BK4547","BK4585"],"gpt_icon":0},{"id":"2557718683","title":"Novavax Inc -Q2 EPS $0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2557718683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557718683?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:49","pubTimestamp":1754480953,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY11R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4568","NVAX","BK4139","BK4547"],"gpt_icon":0},{"id":"2557437302","title":"Commerzbank (0RLW) Gets a Hold from Warburg Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2557437302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557437302?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:56","pubTimestamp":1754477790,"startTime":"0","endTime":"0","summary":"Warburg Research analyst Andreas Plaesier maintained a Hold rating on Commerzbank today and set a price target of €29.20. The company’s shares clos...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/commerzbank-0rlw-gets-a-hold-from-warburg-research-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/commerzbank-0rlw-gets-a-hold-from-warburg-research-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4588","BK4535","BK4139","BK4548","BK4585","BNTX","BK4568"],"gpt_icon":0},{"id":"2557437841","title":"US Health Department Ending Federal mRNA Vaccine Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2557437841","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557437841?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:30","pubTimestamp":1754476236,"startTime":"0","endTime":"0","summary":"The US Health and Human Services Department said Tuesday it will soon end federal mRNA vaccine projects under BARDA, canceling or scaling back 22 efforts worth nearly $500 million.The review found mRNA vaccines were ineffective against upper respiratory infections, and funding will move to broader vaccine platforms, the HHS quoted Secretary Robert Kennedy as saying.The wind-down ends contracts with Emory University and Tiba Biotech and scales back work with Luminary Labs, ModeX, and Seqirus, the department said.It also cancels pre-award solicitations from Pfizer , Sanofi Pasteur , CSL Seqirus, and Gritstone, and restructures collaborations with DoD-JPEO affecting AAHI, AstraZeneca , HDT Bio, and Moderna , the HHS said.Some late-stage contracts with Arcturus and Amplitude will continue to preserve taxpayer investments, and BARDA Ventures will stop mRNA equity funding, the agency added.Future efforts will focus on whole-virus and other vaccine technologies with stronger safety records an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AZN","LU0058720904.USD","BK4501","MRNA","US10Y.BOND","LU0321505868.SGD","SG9999002232.USD","LU0321505439.SGD","BK4550","US6M.BOND","SGXZ57979304.SGD","IE00B19Z3581.USD","IE00BFXG1179.USD","LU1894683264.USD","LU0109394709.USD","IE00BLSP4239.USD","LU0868494617.USD","LU2417539215.USD","LU0306806265.USD","LU2462157665.USD","US5Y.BOND","BK4592","LU0456855351.SGD","LU1066053197.SGD","BK4007","BK4599","SG9999011175.SGD","LU0889565916.HKD","LU1829250122.USD","BK4581","US3Y.BOND","BK4139","BK4568","LU0225771236.USD","LU0289739699.SGD","LU2236285917.USD","PFE.AU","SNY","US30Y.BOND","IE00B19Z3B42.SGD","BK4585","US7Y.BOND","IE00BLSP4452.SGD","BK7095","US2Y.BOND","LU0985481810.HKD","US12M.BOND","LU1066051498.USD","LU0306807586.USD","PFE"],"gpt_icon":1}],"pageSize":20,"totalPage":12,"pageCount":1,"totalSize":238,"code":"91000000","status":"200"}]}}